A BILL to amend and reenact § 54.1-3303.1 of the Code of Virginia, relating to pharmacists; initiation of treatment; influenza prophylaxis.
HB1416 would expand the list of conditions and products that pharmacists in Virginia may initiate, dispense, or administer under a statewide protocol. The bill adds a new category for drugs and devices used for prophylactic purposes to prevent or reduce influenza symptoms, while also retaining and organizing existing pharmacist authority over naloxone, epinephrine, hormonal contraceptives, prenatal vitamins, fluoride supplements, certain over-the-counter items covered by insurance, vaccines, tuberculosis testing, HIV prevention medications, tobacco cessation therapies, and treatment for certain infections guided by waived clinical tests. It also preserves the authority for pharmacists to provide COVID-19 tests and vaccines, including a separate age-based provision for persons age 3 and older.
The bill also sets out patient-safety and care-coordination requirements. Pharmacists must take a patient history, screen for allergies and contraindications, notify a patient’s primary care provider when treatment is initiated if the patient consents, counsel patients who do not have a primary care provider, and provide additional counseling for hormonal contraceptives. Vaccinations must be reported to the Virginia Immunization Information System, and pharmacists may use telemedicine when consistent with existing law and the standard of care. For minors receiving vaccines under the bill, the pharmacist must give written notice to a parent or guardian recommending annual pediatric care.
In terms of state law, HB1416 amends § 54.1-3303.1 of the Code of Virginia, which governs pharmacists’ authority to initiate treatment with and dispense or administer certain drugs and devices. The practical effect would be to broaden pharmacist scope of practice, especially by expressly adding influenza prophylaxis products and reinforcing pharmacist access to preventive care services. It would affect pharmacists, patients seeking preventive or minor acute care, health carriers, and primary care providers who may receive notifications of pharmacist-initiated treatment.
The overall sentiment appears neutral to favorable based on the bill’s introduction and referral, but there is no recorded committee debate or vote history in the provided materials. Because the bill was left in committee, it did not advance in the available record, suggesting either limited support, time constraints, or unresolved policy concerns. The absence of transcripts means no formal public arguments are documented here, but the structure of the bill indicates an emphasis on expanding access to care through pharmacists while maintaining oversight and referral safeguards.
HB1416 would amend Virginia Code § 54.1-3303.1 to expand pharmacists’ authority to initiate, dispense, or administer additional preventive and treatment-related drugs and devices, most notably adding influenza prophylaxis products. It would continue and clarify pharmacist authority over vaccines, COVID-19 testing, HIV prophylaxis, tobacco cessation therapies, and certain other medications and devices, while imposing notification, counseling, history-taking, and reporting requirements. The bill would primarily affect pharmacists, patients age 18 and older for most services, and patients age 3 and older for certain vaccines and tests under the contingent provision.
There is no committee transcript or vote record provided, so the public sentiment cannot be measured from debate. The bill’s introduction and referral suggest it was considered as a health-access measure, but its final status of being left in the House Health and Human Services Committee indicates it did not move forward in the available legislative process. Overall, the bill appears to have been framed as a practical expansion of pharmacist services rather than a controversial policy change, though no direct support or opposition statements are available.
The main policy tension in HB1416 is between expanding pharmacist access to preventive and minor-treatment services and preserving appropriate medical oversight. Potential points of concern include pharmacist authority to initiate treatment for influenza prophylaxis and other conditions, the use of telemedicine, and the extent to which pharmacists may provide services without a traditional physician visit. The bill addresses some of these concerns by requiring patient histories, provider notification when consented to, counseling for patients without primary care providers, and special counseling for contraceptive users and minors receiving vaccines. No specific stakeholder positions are documented in the provided record.